

## **Lupin has entered into an agreement with GSK Philippines**

<b>BSE: 500257</b>	<b>NSE: LUPIN</b>	<b>REUTERS: LUPN.BO</b>	<b>BLOOMBERG: LPC IN</b>
--------------------	-------------------	-------------------------	--------------------------

***Mumbai, 24 October 2005*** : Lupin Limited (India) has entered into an agreement with GSK Philippines whereby Lupin will manufacture and supply the 4 & 2 Drug FDCs to GSK Philippines for marketing in Philippines. The FDC Combinations of TB drugs are based on WHO dosing guidelines.

The Philippines ranks eighth among the 22 countries worldwide with high-burden tuberculosis incidence. According to the World Health Organization's Tuberculosis Control: WHO Report 2004, there were more than 251,000 cases in the Philippines in 2002, with an estimated incidence rate of 320 per 100,000 people.

This arrangement seeks to leverage the intellectual property & technology of Lupin in the area of TB medication, with the strong distribution and marketing infrastructure of GSK in the Philippines.

Commenting on this arrangement, Dr. Kamal Sharma, Managing Director of Lupin Limited said, "This arrangement is a further step forward in Lupin's quest to make available TB drugs efficiently to the geographies most afflicted with the disease".

### **About Lupin**

Headquartered in Mumbai, Lupin (<http://www.lupinworld.com>) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion.11 of Lupin's plants have been approved by the USFDA and two facilities have been approved by the UKMHRA